Klinične študije za Rak dojke v Missouri
75 študij za Rak dojke išče udeležence na lokacijah v Missouri.
Mesta v Missouri
- St. Louis64 študij
- Kansas City34 študij
- Springfield10 študij
- Saint Joseph7 študij
- Lee's Summit7 študij
- Columbia6 študij
- O'Fallon6 študij
- Joplin4 študij
- Cape Girardeau4 študij
- Rolla3 študij
Uradno besedilo študije (angleško)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 45–75 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06995898Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06982521Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- HCA Midwest Division, Kansas City
Vključevanje udeležencevFaza 3
Starost 18–100 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- in še 21
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06172478A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Missouri Cancer Associates, Columbia
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
- in še 1
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06369285Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06625775An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Washington University in St Louis, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07222267A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
- Washington University School of Medicine ( Site 0076), St Louis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, St Louis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07007559A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06966700A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06618287Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07214532Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Kansas City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07085767Cognitive Rehabilitation Following Breast Cancer Treatment
- University of Missouri, Columbia
Vključevanje udeležencev
Starost 20–75 · Ženske · Posodobljeno 22. sep. 2026 · NCT06545045A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Washington University, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07213791A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07174336A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 2
Starost 18 in več · Ženske · Posodobljeno 22. sep. 2026 · NCT07287098A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06827236ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Washington Univ. School of Medicine, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07109726Precision Supplemental Imaging in Women With Dense Breasts
- Washington University School of Medicine, St Louis
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 25–55 · Ženske · Posodobljeno 16. sep. 2026 · NCT07277738A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT05123482A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06253871A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Washington University School of Medicine, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06440005A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Washington University Medical School, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Washington University Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT07100106To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- HCA Midwest Division, Kansas City
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07368998A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- HCA Midwest Health, Kansas City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT06790693Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Oncology Hematology Associates, Springfield
Vključevanje udeležencevOpazovalna študija
Starost 18–99 · Vsi spoli · Posodobljeno 3. sep. 2026 · NCT07211178Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Washington University School of Medicine, St Louis
Vključevanje udeležencevOpazovalna študija
Starost 18–50 · Ženske · Posodobljeno 2. sep. 2026 · NCT06904365Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- in še 29
Vključevanje udeležencevFaza 3
Starost 18–60 · Ženske · Posodobljeno 2. sep. 2026 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07029399Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- WA Uni School Of Med, St Louis
Vključevanje udeležencevFaza 1/2
Starost 18–100 · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT06726148A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Washington University School of Medicine - Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 26. avg. 2026 · NCT07383506A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Washington University, Siteman Cancer Center, St Louis
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06774963Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- in še 2
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Vse starosti · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT02302742Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.